Individualized Fortification of Breast Milk

Sponsor
Ozgul Bulut (Other)
Overall Status
Completed
CT.gov ID
NCT03324126
Collaborator
(none)
32
5.9

Study Details

Study Description

Brief Summary

Objectives: To compare the effects of two different methods of individualized protein fortification of breast milk on the early growth of VLBW preterm infants.

Design: VLBW preterm infants ≤ 32 weeks of gestational age were included in the study and randomized into two groups according to the method of breast milk fortification. In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day. In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was < 5 mg/dL, the amount of protein fortification was gradually increased to an "estimated" maximum level of 4.5 g/kg/day, as per the policy of neonatal intensive care unit. The cumulative amounts of protein, energy, fat, and carbohydrate given to infants prior to study commencement and during the study period were calculated. Anthropometric measurements were performed in both groups weekly for 4 weeks to compare their growth, and blood data including pH, base deficit, and urea, creatinine, and albumin levels were collected.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Optimal feeding during the early neonatal period is critical because inadequate nutrition, especially of very-low-birth-weight (VLBW) preterm infants, causes growth restrictions and has negative effects on neurocognitive development (1-5).

    Although breast milk is the first choice for nutrition of preterm infants (6, 7), it falls short of meeting all of the nutritional needs of VLBW infants unless fortified (8-10). Therefore, standard fortification (addition of a fixed amount of a commercial fortifier to breast milk) has become a commonly used method in neonatal intensive care units (NICUs) (11, 12). Standard fortification is performed based on assumptions made about the protein level in breast milk. However, protein levels show inter- and intra-individual variation, and the assumed levels in the milk of the mothers of preterm infants (2.1-2.4 g/100 kcal) is reduced to <1.5 g/100 kcal after the 14th day of lactation (10, 13-17). The protein content of commercial fortifiers ranges from 0.7 to 1.1 g/100 mL, and they thus can only increase the amount of protein in breast milk to 3.25 g/100 kcal. Therefore, the standard fortification method fails to meet the daily protein need of 3.5-4.5 g/kg/day of VLBW infants that is recommended by the European Society for Pediatric Gastroenterology Hepatology and Nutrition (18, 19).

    Individualized fortification is another method recommended for optimizing breast milk fortification, and it is considered the best solution for addressing the protein deficiencies of VLBW preterm infants (10, 12). There are two valid methods of individualized fortification: "targeted fortification" based on analyses of breast milk proteins, and "adjustable fortification" based on the blood urea nitrogen (BUN) - reflected metabolic response of infants (10, 12). Despite these developments, there is still no consensus on the optimum fortification method; many different protocols are applied in NICUs worldwide (20, 21).

    To the best of the investigators knowledge, no study has yet compared these two individualized fortification methods for nutrition of preterm infants. Therefore, the investigators compared the effects of targeted and adjustable protein fortification on the early growth of breastfed VLBW preterm infants.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    32 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Effects of Targeted Versus Adjustable Protein Fortification of Breast Milk on Early Growth in Very-low-birth-weight Preterm Infants: A Randomized Clinical Trial
    Actual Study Start Date :
    Sep 1, 2013
    Actual Primary Completion Date :
    Dec 1, 2013
    Actual Study Completion Date :
    Feb 28, 2014

    Arms and Interventions

    Arm Intervention/Treatment
    Targeted fortification

    In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day.

    Adjustable fortification

    In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was < 5 mg/dL, the amount of protein fortification was gradually increased to an "estimated" maximum level of 4.5 g/kg/day

    Outcome Measures

    Primary Outcome Measures

    1. Weight gain [4 weeks]

      The mean of weight gain (g/kg/day)

    2. Head circumference [4 weeks]

      The mean of head circumference (mm/week)

    3. Length [4 weeks]

      The mean of length (mm/week)

    Secondary Outcome Measures

    1. Blood Urea Nitrogen (BUN) [4 weeks]

      The mean of BUN (mg/dL)

    2. Albumin [4 weeks]

      The mean of albumin (g/dL)

    3. Base deficit [4 weeks]

      The mean of base deficit (mEq/L)

    4. Protein content [4 weeks]

      The mean of total daily intake of protein (g/kg/day)

    5. Calorie intake [4 weeks]

      The mean of total daily intake of calorie (kcal/kg/day)

    6. Carbonhydrate content [4 weeks]

      The mean of total daily intake of carbohydrate (g/kg/day)

    7. Lipid content [4 weeks]

      The mean of total daily intake of lipid (g/kg/day)

    8. Protein/Energy Ratio [4 weeks]

      The mean of total daily intake of Protein\Energy Ratio

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Weeks to 32 Weeks
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Very-low-birth-weight preterm infants ≤ 32 weeks of gestational age who were fed exclusively fortified breast milk.
    Exclusion Criteria:
    • The exclusion criteria were any congenital abnormality, a metabolic disease, necrotizing enterocolitis, bronchopulmonary dysplasia, and feeding with formula or formula plus breast milk.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Ozgul Bulut

    Investigators

    • Study Director: Zeynep Ince, Prof., Istanbul University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ozgul Bulut, Principal Investigator, Istanbul University
    ClinicalTrials.gov Identifier:
    NCT03324126
    Other Study ID Numbers:
    • 35496
    First Posted:
    Oct 27, 2017
    Last Update Posted:
    Oct 27, 2017
    Last Verified:
    Oct 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ozgul Bulut, Principal Investigator, Istanbul University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 27, 2017